期刊文献+

E.coli表达HEV ORF2编码蛋白第112~607氨基酸片段的免疫原性及其诱生抗体的病毒中和活性 被引量:2

Immunogenicity of Amino Acids 112-607 of A Recombinant HEV ORF2-Encoded Protein Expressed in E. cott and Neutralizing Capacity of Antibodies Elicited by Its Immunization in Animals
下载PDF
导出
摘要 目的 探讨E.coli表达的戊型肝炎病毒(HEV)ORF2编码蛋白第112~607氨基酸片段(pORF2-56K)的免疫原性及其诱生抗体的病毒中和活性。方法 pORF2-56K免疫小鼠和豚鼠,用ELISA检测血清抗体效价。将HEV毒种与高效价豚鼠灭活血清在体外孵育后,接种于2BS细胞,用RT-PCR检测病毒RNA的复制情况。结果E.coli表达的pORF2-56K可诱导机体产生高水平的HEV特异性抗体和强烈的免疫记忆。该抗体可在体外有效中和HEV,使之失去在2BS细胞中有效复制的能力。结论 E-coli表达的pORF2-56K具有良好的免疫原性,且其诱生抗体具有中和HEV的能力,可作为HEV重组疫苗的候选抗原。 Objective To explore the immunogenicity of pORF2-56K,a recombinant HEV ORF2-en-coded protein (aminp acids 112-607) expressed in E. coli, as well as the neutralizing capacity of antibodies induced with it. Methods Immunize mice and guinea pigs with pORF2-56K and detect serum antibody liters by ELISA. Incubate HEV strain with inactivated guinea pig sera at high liters, inoculate into 2BS cells and detect the replication of viral RNA by RT-PCR. Results The pORF2-56K expressed in E. coli induced a high HEV-specific antibody level and a strong immune memory.The antibody neutralized HEV in vitro and prevented it from replication in 2BS cells. Conclusion The pORF2-56K expressed in E. coll showed good immunogenicity , and the antibody induced with it showed neutralizing capacity to HEV. So pORF2-56K might be used as a candidate antigen for the development of a recombinant HEV vaccine.
出处 《中国生物制品学杂志》 CAS CSCD 2003年第5期264-266,共3页 Chinese Journal of Biologicals
关键词 表达 HEVORF2编码蛋白 氨基酸片段 免疫原性 诱生抗体 中和活性 戊型肝炎病毒 Hepatitis E Virus ORF 2 Immunogenicity Neutralizing capacity
  • 相关文献

参考文献10

  • 1毕胜利,刘崇柏,曹学义,赵洪兰,H.S.Margolis.我国戊型肝炎病毒基因组cDNA全序列测定及分析[J].病毒学报,1992,8(3):271-279. 被引量:26
  • 2马雁冰,孙茂盛,李鸿钧,唐浩,杜瑞娟,李春宏,张光明,谢天宏,戴长柏.戊型肝炎病毒ORF2 C端抗原片段的表达及其免疫学特性研究[J].中华微生物学和免疫学杂志,2000,20(5):419-422. 被引量:4
  • 3Koonin EV, Gorbaleya AE, Purdy MA,et al. Computer-assisted assignment of functional domains the nonstructural polyprotein of hepatitis E vius: delineation of an addtional group of positive-strand RNA plant and animal viruses. Proc Natl Acad Sci U S A,1992,89(17):8259-8263.
  • 4Korkaya H,Jameel S, Gupta D, et al. The ORF3 protein of hepatitis E virus binds to Src homology 3 domains and activated MARK. J Biol Chem, 2001,276 (45): 42389-42400.
  • 5Tsarev SA, Tsareva TS, Emerson SU, et al. Recombinant vaccine against hepatitis E: doee response and protection against heterologous challenge. Vaccine, 1997,15(17-18): 1834-1838.
  • 6Huang CC, Nguyen D, Femandez J,et al. Molecular doning and sequencing of the Mexico isolate of hepatitis E vires (HEV). Virology, 1992,191(2) :550-558.
  • 7Huang R, Nakazono N, Ishii K, et al. Hepatitis E virus(87A strain)propagated in A549 cells.J Med Virol, 1995,47(4):299-302.
  • 8Quiroga JA, Cotonat T, Castillo I,et al.Hepatitis E virus seroprevalence in acute viral hepatitis in a developed country confirmed by a supplemental assay. J Med Viral,1996,50(1):16-19.
  • 9Tsarev SA,Tsareva TS,Emerson SU,et al. Successful passive and active immunization of cynomolgus monkeys against hepatitis E. Proc Nat1 Acad Sci U S A,1994,91(21):10198-10202.
  • 10Peter D. Immunity to viruses. Immunologist, 1995,3(5-6) :231-233.

二级参考文献8

共引文献28

同被引文献39

  • 1Khuroo MS, Kamili S. Aetiology and prognostic factors in acute liver failure in India [J]. J Viral Hepat 2003; 10: 224-31.
  • 2Shrestha SM, Shrestha S, Tsuda F, et al. Molecular investigation of hepatitis E virus infection in patients with acute hepatitis E in Kathmandu [J] .Nepal. J Med Virol 2003; 69:207 - 14.
  • 3Isaaecson M, Frean J, He J, et al. An outbreak of hepatitis E in northern Namibia [J] .Am J Trop Med Hyg 2000; 62: 619-25.
  • 4Labrique AB, Thomas DL, Stoszek SK, et al. Hdpatitis E: an emerging infectious disease [J]. Epidemiol Rev 1999; 21: 162-79.
  • 5Ghabrah TM, Tsarev S, Yarbough PO, et al. Comparison of tests for antibody to hepatitis E virus [J]. J Med Virol 1998; 55: 134-7.
  • 6Khudyakov YE, Lopareva EN, Jue DL, et al. Antigenic domains of the open reading frame 2-encoded protein of hepatitis E virus [J]. J Clin Microbiol 1999; 37:2863-71.
  • 7Meng J, Dai X, Chang JC, et al. Identification and characterization of the neutralizing epitope (s) of the hepatitis E virus [J]. Virology2001; 288: 203-11.
  • 8PurdyMA, McCaustlandKA, KrawczynskiK, et al. Preliminary evidence that a trp E-HEV fusion protein protects cynomolgus macaques against challenge with the wild-type hepatitis E virus (HEV) [J]. J Med Virol 1993; 41: 90-4.
  • 9ImSW, ZhangJZ, Zhuang H, et al. A bacterially expressed peptide prevents experimental infection of primates by the hepatitis E virus[J]. Vaccine2001; 19: 3726-32.
  • 10Yarbough PO. Hepatitis E virus: advances in the HEV biology and HEV vaccine approaches [J]. Intervirology 1999; 42:179 - 84.

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部